Artificial Intelligence in Diabetes Management Market Summary

The Global AI in Diabetes Management Market size was valued at USD 1,568.64 Million in 2024, and the market is projected to grow from USD 1,925.66 Million in 2025 to USD 14,239.56 Million by 2035, registering a CAGR of 22.76% during the forecast period 2025–2035. North America led the global market in 2025 with over 40% share, generating around USD 627.46 Million in revenue.

The global market is experiencing substantial growth due to the rising global diabetes burden, increasing adoption of AI-powered monitoring technologies, and growing demand for personalized treatment solutions. Advancements in predictive analytics, continuous glucose monitoring, and digital healthcare platforms are further accelerating market expansion worldwide.

According to the World Health Organization, more than 830 million people were living with diabetes globally in 2024, compared with approximately 200 million cases in 1990. WHO also reported that diabetes directly caused around 1.6 million deaths annually, increasing demand for AI-driven technologies that enable early intervention, personalized treatment planning, and continuous remote monitoring.

Key Market Trends & Highlights

The AI in Diabetes Management Market is rapid advancements in predictive tools, personalized systems, and integrated devices, driven by rising diabetes cases worldwide.

North America generated over 45% global revenue in 2024 through advanced healthcare infrastructure and strong AI technology adoption.
Europe market reached USD 392.16 million in 2024, contributing approximately 25% global market share.
Cloud-based deployment captured 61.7% share in 2024, supported by scalable infrastructure and remote monitoring capabilities.
Hospitals and clinics represented 66.1% market demand through increasing investment in AI-driven diabetes monitoring and treatment platforms.

Market Size & Forecast

2024 Market Size	1,568.64 (USD Million)
2035 Market Size	14,239.56 (USD Million)
CAGR (2025 - 2035)	22.76%

Major Players

Companies such Eli Lilly and Company, AstraZeneca, Sanofi, Novo Nordisk A/S, Tandem Diabetes Care, Inc., F. Hoffmann-La Roche Ltd, Abbott, Medtronic, Dexcom, Inc., Insulet Corporation are some of the major participants in the global market.

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

Artificial Intelligence in Diabetes Management Market Trends

The AI in Diabetes Management Market is experiencing rapid growth driven by technological advancements, the rising prevalence of diabetes, and increasing demand for personalized, data-driven healthcare solutions. AI applications in diabetes management encompass a variety of medical devices and software, including continuous glucose monitors (CGMs), smart insulin delivery systems, digital therapeutics, and AI-powered analytics platforms that facilitate real-time monitoring, predictive modeling, and personalized treatment.

According to Institute for Health Metrics and Evaluation, diabetes remained among the top 10 contributors to global disease burden in 2024, with millions requiring continuous long-term monitoring. AI-enabled predictive analytics are increasingly being adopted to reduce diabetes-related complications, improve glycemic stability, and support scalable chronic disease management strategies globally.

A significant driver of the global market is the escalating global diabetes incidence, which calls for efficient and scalable management tools. AI helps optimize insulin dosing, predict glycemic trends, and support individualized care plans, leading to improved metabolic control and reduced complications. Integration of cloud computing and mobile health technologies is further enhancing remote monitoring and telemedicine capabilities, allowing for continuous patient engagement outside clinical settings.

However, the global market also faces challenges such as data privacy and cybersecurity concerns, high implementation and integration costs, and limited interoperability across devices and electronic health record (EHR) systems, which could hinder widespread adoption especially in resource-constrained environments.

Geographically, North America leads the global market, supported by advanced healthcare infrastructure, established AI companies, and a high diabetes burden. Meanwhile, Asia Pacific is expected to witness the fastest growth, driven by rising healthcare investments, a large pool of diabetes patients, and increasing digital health adoption.

Artificial Intelligence in Diabetes Management Market Drivers

Rising Global Diabetes Prevalence

AI is proven transformative in addressing these challenges, offering personalized treatment planning and real-time disease monitoring. For example, AI-driven platforms combine continuous glucose monitoring (CGM) and wearable technologies, enabling patients and clinicians to better control blood glucose levels and minimize complications.

In China, AI-powered systems guide lifestyle modification, medication adjustments, and insulin delivery, reportedly improving self-management and adherence. Globally, AI algorithms are being used for automated retinal screening to detect diabetic retinopathy, predicting individual risk for diabetes, and optimizing drug prescriptions using machine learning techniques.

Advancements in Connected Devices and Digital Health Infrastructure

Advancements in connected devices and digital health infrastructure have emerged as crucial drivers for the global adoption and effectiveness of artificial intelligence (AI) in diabetes management. Technologies such as continuous glucose monitors (CGMs), smart insulin pens, AI-enabled smartwatches, and integrated mobile health applications are fundamentally transforming patient engagement, glycemic control, and treatment adherence.

Wearables like Perspirion Diagnostics’ sweat-based glucose monitors and Daia Health’s emergency alert app further exemplify how digital infrastructure enhances safety, self-management, and real-time responsiveness for diabetics.

Market Segment Insights

By Type: Diagnostics (Largest) vs. Treatment Planning (Fastest-Growing)

In the AI in Diabetes Management Market, the diagnostics segment dominates the gloal market, accounting for the largest share of 63.2%. This segment encompasses advanced AI tools that facilitate accurate and early detection of diabetes-related complications, leading to better patient outcomes. Treatment planning follows as a prominent area, leveraging AI to customize treatment strategies based on individual patient data, thereby improving the effectiveness of diabetes management.

Algorithms: Diagnostics (Dominant) vs. Treatment Planning (Emerging)

The diagnostics segment leverages advanced algorithms to analyze data from various sources, such as wearable devices and medical records, allowing healthcare professionals to diagnose diabetes-related issues timely and effectively. In contrast, the treatment planning segment is emerging as a critical component in the management of diabetes, using AI algorithms to create tailored treatment plans for patients. This segment focuses on analyzing large datasets to propose optimal medication and lifestyle adjustments, thereby enhancing patient adherence and health outcomes during the diabetes management process.

By Application: Type 2 Diabetes (Largest) vs. Type 1 Diabetes (Fastest-Growing)

In the AI in Diabetes Management Market, Type 2 Diabetes holds the largest share among the application segments, accounting for 72.5% of the market. This dominance stems from the growing prevalence of Type 2 Diabetes globally, leading to increased demand for intelligent management solutions that can personalize treatment protocols. The widespread acceptance of these solutions among healthcare providers and patients further solidifies its market position, making Type 2 Diabetes the primary focus for AI applications in diabetes management. On the other hand, Type 1 Diabetes represents the fastest-growing segment in this market. As advancements in technology drive innovations in AI applications, solutions tailored specifically for Type 1 Diabetes are gaining traction. Factors such as rising awareness about diabetes management, the need for continuous monitoring, and the swift adaptation of AI technology in medical settings contribute to the rapid growth of this segment. This dual trend of dominance and growth encapsulates the dynamic nature of the global market dynamics in diabetes management.

Type 2 Diabetes: Dominant vs. Type 1 Diabetes: Emerging

Type 2 Diabetes currently stands as the dominant application segment within the global market, leveraging a robust framework of established data analytics and personalized care solutions. These solutions utilize AI algorithms that analyze various health parameters, leading to proactive monitoring and improved patient outcomes. The integration of wearables and mobile applications has enhanced patient engagement, making management more interactive and effective. Conversely, Type 1 Diabetes, classified as an emerging segment, shows significant potential for growth. Innovations such as automated insulin delivery systems and continuous glucose monitoring powered by AI illustrate the market's shift towards tailored management for Type 1 patients. The recent emphasis on real-time data analysis and machine learning ensures that Type 1 Diabetes management solutions are not just reactive but predictive, thus improving the overall quality of life for patients.

By Deployment: Cloud-Based (Largest) vs. Software as a Service (SaaS) (Fastest-Growing)

In the AI in Diabetes Management Market, the Deployment segment showcases a dynamic landscape, with Cloud-Based solutions holding the largest market share at 61.7%. Enterprises increasingly prefer cloud solutions due to their scalability, accessibility, and cost-effectiveness, making them a dominant choice for diabetes management applications. In contrast, Software as a Service (SaaS) is emerging rapidly, appealing to healthcare providers who favor subscription models that reduce upfront investments while ensuring continuously updated AI technologies.

Deployment: Cloud-Based (Dominant) vs. On-Premise (Emerging)

Cloud-Based deployment stands out as the dominant choice due to its ability to enable real-time data processing and remote monitoring, essential for managing diabetes effectively. It supports vast data storage and seamless integration with various health systems, enhancing patient outcomes through timely interventions. On-Premise solutions, while offering higher data security and control, are seeing a steady emergence as organizations seek tailored implementations that align closely with their existing IT infrastructure. However, the flexibility and innovation associated with Cloud-Based systems position it favorably as the cornerstone for future advancements in AI applications for diabetes management.

By End User: Hospitals and Clinics (Largest) vs. Diabetes Treatment Centers (Fastest-Growing)

In the AI in Diabetes Management Market, Hospitals and Clinics represent the largest end-user segment, accounting for 66.1% of the market and leveraging advanced technologies for patient care and management. This segment dominates due to its comprehensive resources and integration of AI for monitoring and treatment, capturing a significant portion of the market. On the other hand, Diabetes Treatment Centers are emerging as a fast-growing segment, focused on specialized care and personalized treatment approaches, driven by increasing patient awareness and the need for advanced diabetes management solutions. The growth trends within this segment are driven by the rising prevalence of diabetes worldwide and the growing adoption of AI technologies in various healthcare settings. Hospitals and Clinics continue to invest in AI-driven systems to enhance patient outcomes and operational efficiency, while Diabetes Treatment Centers rapidly expand their services through innovative AI applications. The emphasis on personalized medicine and improved patient engagement is boosting the growth of both segments, with a significant shift towards outpatient care and personalized diabetes management solutions.

Hospitals and Clinics (Dominant) vs. Diabetes Treatment Centers (Emerging)

Hospitals and Clinics represent the dominant force in the global market, providing extensive services that integrate AI for comprehensive patient management. These institutions typically have robust resources and infrastructure, enabling them to utilize AI-driven tools for diagnostics, real-time monitoring, and personalized treatment plans. The dominance of this segment is characterized by established practices, extensive patient networks, and ongoing investments in technology to enhance care delivery. In contrast, Diabetes Treatment Centers are emerging as a key player focusing on specialized diabetes care, often tailored to individual patient needs. These centers harness AI technology to refine treatment protocols and facilitate continuous patient engagement, thus redefining diabetes management strategies. With their adaptive approaches, these centers are growing swiftly in terms of both patient numbers and service offerings.

Get more detailed insights about Artificial Intelligence in Diabetes Management Market

Request Free Sample

Regional Insights

North America: Fastest growing diabetes management

North America leads in the AI in Diabetes Management Market size, accounting for over 45% of the global revenue in 2024. North America leads the global market, driven by high prevalence, advanced healthcare infrastructure, and heavy investment in cloud-based platforms. The region commands over 40% market share, with rapid adoption in hospitals, clinics, and patient apps amid rising Type 2 and gestational cases.

According to the Centers for Disease Control and Prevention, over 38.4 million Americans were living with diabetes in 2024, while approximately 97.6 million adults had prediabetes. The increasing burden of chronic metabolic diseases and strong digital health adoption are significantly accelerating demand for AI-powered diabetes monitoring and predictive analytics platforms throughout North America.

Primary care clinics favor hybrid models, with Doctors App-like EMRs in urban centers streamlining T2D workflows. Canadian clinics leverage AI for gestational diabetes (GDM) screening, where models like ANN predict risk at 83% sensitivity using BMI and glucose data. Over 60% of U.S. endocrinologists report AI boosts efficiency. Patients access apps like mySugr for photo-based carb logging and real-time TIR coaching, improving adherence by 50%. Wearables (Dexcom G7) feed AI for personalized dosing, with RCTs showing 1-2% HbA1c drops. Accessibility shines in underserved areas via low-cost cloud sync.

Artificial Intelligence in Diabetes Management Market Regional Insights

Europe: Strong Production diabetes management

Europe AI in Diabetes Management Market size was valued at USD 392.16 million in 2024, making it the second-largest regional market with a 25% share. In Europe, holds a strong position in the global AI diabetes management market, with approximately 25% share driven by robust healthcare systems, EU-wide digital health initiatives, and stringent data regulations like GDPR.

According to the World Health Organization European health estimates, more than 60 million people across Europe are currently living with diabetes, creating substantial demand for AI-enabled monitoring and predictive care technologies. Expanding adoption of connected healthcare systems and data-driven disease management solutions continues supporting strong regional market growth.

The region benefits from high diabetes prevalence over 60 million cases and leaders like Germany, UK, France, and Netherlands pioneering AI integration in diagnostics, monitoring, and care. European hospitals favor cloud-hybrid systems compliant with GDPR and eHealth standards. Platforms like Glooko connect 200+ devices to EMRs, enabling population dashboards for TIR tracking across wards. Glytec-like dosing AI reduces errors by 70% in ICUs, with ROI from shorter stays. EU projects like AI4Health fund on-premises options for data sovereignty in networks like Charité Berlin.

Asia Pacific: Expanding diabetes management

Asia Pacific commands a rapidly expanding share of the global AI in diabetes management market, fueled by massive diabetes prevalence, smartphone penetration, and government-backed digital health initiatives. The region, with nearly half the world's cases (over 250 million), drives explosive growth through affordable wearables, cloud platforms, and AI predictive tools tailored to diverse populations.

Hospitals dominate with 58% market share, using cloud EMRs for AI glucose dashboards. Apollo in India deploys analytics for risk stratification; Singapore/Australia clinics integrate CGMs with population tools. Software platforms hold 42.8% segment share, enabling real-time TIR tracking and complication alerts.

South America: Growing diabetes management

South America faces a surging diabetes burden, with AI management systems emerging as cost-effective solutions amid limited resources and high prevalence. The region trails North America and Europe in adoption but shows promise through mobile-first cloud platforms and public health pilots targeting Type 2 dominance. Public hospitals adopt hybrid cloud-on-premises systems for affordability.

Platforms sync CGM data to dashboards, reducing ICU hypo events by 30-50%. Local servers process high-volume T2D cohorts, with FHIR enabling EMR ties despite legacy challenges. Clinics prioritize mobile apps for self-management, with AI bolus calculators and photo-carb logging boosting TIR 10-15%. Patients in urban favelas use free WhatsApp bots for reminders; rural telemedicine cuts travel via satellite-linked wearable.

Middle East & Africa: Emerging diabetes management

In Middle East & Africa (MEA) represent an emerging frontier for AI in diabetes management, grappling with the world's highest regional prevalence amid resource constraints, urbanization, and mobile tech leaps. AI tools focus on affordable screening, telemedicine, and apps to bridge gaps in underserved areas.

Urban hospitals in UAE/South Africa deploy cloud hybrids like Glooko for CGM dashboards, integrating with local EMRs to cut hypo events 30%. On-premises servers handle retinopathy AI screening (95% sensitivity) in resource hubs like Riyadh or Johannesburg. Public systems emphasize population analytics for T2D cohorts.

Key Players and Competitive Insights

Many global, regional, and local vendors characterize the AI in Diabetes Management Market. The global industry is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth.
The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market. The major players in the global market Include Eli Lilly and Company, AstraZeneca, Sanofi, Novo Nordisk A/S, Tandem Diabetes Care, Inc., F. Hoffmann-La Roche Ltd, Abbott, Medtronic, Dexcom, Inc., Insulet Corporation strategic market developments and decisions to improve operational effectiveness.

Industry Developments

March 2025: Insulet Corporation Commercially available in Australia; launching soon in Belgium, Canada, and Switzerland. Expanded sensor integrations with Dexcom G6/G7 and Abbott Freestyle Libre 2 Plus. Plans to launch in Israel, Saudi Arabia, UAE, Qatar, and Kuwait. First tubeless AID system communicating with CGM, automatically adjusts insulin every 5 minutes, improves clinical outcomes, waterproof Pod, wearable, controlled via smartphone or Omnipod Controller.

June 2025: Medtronic announced a $50M investment over five years to open a Diabetes Global Capability Center in Pune, India, creating 300 jobs. It also plans to spin off its diabetes business as a standalone company named “MiniMed” to enhance strategic focus and innovation in diabetes care.

May 2024: Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the pharma and life sciences industries. Sanofi will leverage this partnership to provide access to proprietary data to develop AI models as it continues its path to becoming the first biopharma company powered by AI at scale.

Future Outlook

Artificial Intelligence in Diabetes Management Market Future Outlook

The AI in Diabetes Management Industry size is projected to reach USD 14,239.56 million by 2035, growing at a CAGR of 22.76%, driven by increasing demand for high-performance computing and enhanced security features.

New opportunities lie in:

Expansion of Remote Patient Monitoring (RPM) and Telehealth
Emergence of Generative AI and Predictive Analytics
Partnerships Between Tech Giants and Healthcare Providers.

By 2035, theAI in Diabetes Management Industry is expected to be robust, driven by innovation and strategic partnerships.

Market Segmentation

AI in Diabetes Management Market by Type Outlook

Diagnostics
Treatment Planning
Data Management
Patient Self-Management

AI in Diabetes Management Market End User Outlook

Hospitals and Clinics
Ambulatory Surgical Centers
Diabetes Treatment Centers
Patients

AI in Diabetes Management Market Application Outlook

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

AI in Diabetes Management Market by Deployment Outlook

Cloud-Based
On-Premise
Hybrid

Report Scope

Market Size 2024	1,568.64 (USD Million)
Market Size 2025	1,925.66 (USD Million)
Market Size 2035	14,239.56 (USD Million)
Compound Annual Growth Rate (CAGR)	11.76% (2025 - 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2023
Market Forecast Units	USD Million
Key Companies Profiled	Eli Lilly and Company, AstraZeneca, Sanofi, Novo Nordisk A/S, Tandem Diabetes Care, Inc., F. Hoffmann-La Roche Ltd, Abbott, Medtronic, Dexcom, Inc., Insulet Corporation.
Segments Covered	By Type, By Deployment, By Application, By End User
Key Market Opportunities	Expansion of Remote Patient Monitoring (RPM) and Telehealth. Emergence of Generative AI and Predictive Analytics. Partnerships Between Tech Giants and Healthcare Providers.
Key Market Dynamics	Advancements in Connected Devices and Digital Health Infrastructure. Shift Toward Personalized and Predictive Healthcare. Increased Adoption of Cloud and SaaS Healthcare Platforms. Limited Interoperability Across Devices and EHR Systems.
Region Covered	North America, Europe, Asia Pacific, South America, Middle East & Africa.

FAQs

What is the projected market valuation for the AI in Diabetes Management Market by 2035?

The global market is projected to reach a valuation of 15.44 USD Billion by 2035.

What was the global market valuation for the AI in Diabetes Management Market in 2024?

The overall market valuation was 1.188 USD Billion in 2024.

What is the expected CAGR for the AI in Diabetes Management Industry during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 26.26%.

Which segment is projected to have the highest valuation in the AI in Diabetes Management Market by 2035?

The Type 2 Diabetes segment is projected to have the highest valuation, reaching 10.0 USD Billion by 2035.

What are the key applications of Artificial Intelligence in Diabetes Management?

Key applications include Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes, with Type 2 Diabetes leading in market size.

Which deployment model is expected to dominate the AI in Diabetes Management Industry?

The Software as a Service (SaaS) model is expected to dominate, with a projected valuation of 6.78 USD Billion by 2035.

Who are the leading companies in the global market?

Key players include Abbott Laboratories, Medtronic, Roche, and Dexcom, among others.

What is the projected valuation for the Patient Self-Management segment by 2035?

The Patient Self-Management segment is projected to reach a valuation of 5.0 USD Billion by 2035.

How does the global industry for Diabetes Treatment Centers compare to other end users?

The Diabetes Treatment Centers segment is projected to reach 3.0 USD Billion by 2035, indicating substantial growth.

What is the anticipated growth trend for the Data Management segment in the AI in Diabetes Management Market?

The Data Management segment is expected to grow to 3.0 USD Billion by 2035, reflecting increasing demand for data-driven solutions.

Author

Author

Rahul Gotadki

Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment